What Prostamax Is
Prostamax is a synthetic tetrapeptide, Lys-Glu-Asp-Pro (KEDP), C20H33N5O9, 487.51 g/mol. Within the bioregulator family it is the prostate-associated member, and it is Vesugen's KED tripeptide extended by a proline.
Two published studies name it. Both are worth reading for what they are not: neither is a prostate study.
Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.
What the Two Studies Report
Heterochromatin in human lymphocytes
The primary paper examines the influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ (Meskhi et al., Biofizika 2004, PMID 15612551).
This is a direct test of the family's central proposition — that short peptides act on chromatin — carried out in primary human cells rather than inferred from a downstream phenotype. It is the same experimental line as the Livagen chromatin work, and the two are best read together.
Microcalorimetry with metal ions
A second study used microcalorimetry on human blood lymphocyte cultures in the presence of copper, cadmium and prostamax (Kiladze et al., Georgian Med News 2009, PMID 19359734). The design is biophysical — it measures heat exchange in cell cultures — and the peptide appears alongside metal ions rather than as a sole intervention.
What the Prostate Label Rests On
Nothing in either paper concerns prostate tissue. The prostate association comes from the family's classification scheme, not from a published experiment on this sequence.
That does not make the label wrong; it makes it untested. If prostate activity is the research question, that gap belongs in the design rather than in the citation list.
Structure and Handling
- Sequence. Lys-Glu-Asp-Pro (KEDP), tetrapeptide.
- Formula. C20H33N5O9, 487.51 g/mol.
- Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
- Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
- Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.
Related Compounds
KEDP is KED plus proline. Vesilut (Glu-Asp) is a fragment contained within it. Pancragen (KED + Trp) has the family's largest literature. Full set on the bioregulator overview.
Research Studies at a Glance
The two indexed studies of Prostamax (KEDP) address distinct experimental questions and use different biophysical methods. Neither has been replicated by an independent group, and no dose-response or concentration data are reported in the publicly available abstracts. The table below summarises what the record actually contains; any cell marked "not reported" reflects an absence in the source, not an omission here.
| Study | Year | Model | Intervention / Design | Key Finding | PMID |
|---|---|---|---|---|---|
| Meskhi et al., Biofizika | 2004 | Human lymphocytes, in situ | KEDP applied to primary human lymphocyte cultures; heterochromatin assessed by unspecified cytological method | Reported influence on heterochromatin organisation; quantitative parameters not reported in abstract | [1] 15612551 |
| Kiladze et al., Georgian Med News | 2009 | Human blood lymphocyte cultures, in vitro | Microcalorimetry of cultures co-exposed to copper, cadmium, and KEDP; KEDP not tested as sole agent | Altered heat-exchange profiles in the presence of metal ions; peptide-specific contribution not isolated | [2] 19359734 |
Two design features constrain interpretation across both studies. First, the lymphocyte model was chosen to test the bioregulator family's chromatin hypothesis — it is not a prostate-relevant tissue. Second, the 2009 microcalorimetry study is a multi-agent design: because KEDP was not tested in isolation, any thermal signal attributed to it carries confounding from the metal-ion co-treatments. These are not disqualifying limitations; they define the questions that remain open for follow-up work.
Proposed Chromatin Interaction Mechanism
No published study has traced the intracellular signalling cascade downstream of KEDP in molecular detail. What follows is the mechanistic framework the Khavinson bioregulator programme uses to interpret the family's chromatin effects — classified here as proposed, because direct receptor identification and pathway mapping for KEDP specifically have not been reported.
The central proposition of the tetrapeptide bioregulator class is that short, charged peptides interact with nucleosomal DNA or histone tails through electrostatic and hydrogen-bond contacts, and that this interaction shifts the local equilibrium between euchromatin and heterochromatin. KEDP carries a net anionic character at physiological pH (lysine +1, glutamate −1, aspartate −1, proline neutral: net −1), which distinguishes it from the cationic peptides — such as protamines and certain histone N-terminal domains — that compact chromatin. A peptide with net negative charge at the concentrations used in cell-culture assays might instead compete with, or displace, endogenous anionic regulators at histone-binding sites. This is a plausible but unverified mechanism: it has not been tested with recombinant histones, and no binding constant for KEDP–nucleosome interaction has been published.[1]
The Meskhi et al. study[1] is consistent with a chromatin-accessibility effect, in that it reports a change in heterochromatin distribution in intact lymphocytes. However, the in situ design does not discriminate between a direct peptide–chromatin contact and an indirect route involving membrane receptors, second messengers, or altered transcription factor activity. All three pathways remain open hypotheses. Until binding assays with isolated chromatin components are published for KEDP specifically, the mechanism sits in the proposed register regardless of what has been demonstrated for the broader bioregulator family.
The co-exposure design of the Kiladze et al. study[2] raises a separate mechanistic question: whether KEDP modulates metal-ion uptake, chelates copper or cadmium extracellularly, or affects mitochondrial thermogenesis independently. The aspartate and glutamate residues confer weak metal-chelating potential, but no binding stoichiometry or affinity constant has been reported for KEDP with either ion. This, too, is an open experimental question rather than a settled finding.
Structural Comparison with Related Bioregulators
KEDP belongs to a family of short regulatory peptides developed within the same research programme. Comparing it structurally with its nearest relatives clarifies both what is shared across the family and what makes KEDP's sequence distinct. No head-to-head pharmacological comparison of these peptides has been published; the table below is therefore a structural comparison derived from sequence and formula data, not an efficacy comparison.
| Compound | Sequence | Length | Formula | MW (g/mol) | Net charge (pH 7.4, approx.) | Tissue label | Published human-cell chromatin data |
|---|---|---|---|---|---|---|---|
| Prostamax (KEDP) | Lys-Glu-Asp-Pro | 4-mer | C₂₀H₃₃N₅O₉ | 487.51 | −1 | Prostate (by classification) | Yes — Meskhi et al. 2004[1] |
| Vesugen (KED) | Lys-Glu-Asp | 3-mer | C₁₅H₂₆N₄O₈ | 394.39 | −1 | Vascular | Not identified in public record |
| Livagen (KHLGE) | Lys-His-Leu-Gly-Glu | 5-mer | C₂₄H₄₁N₇O₉ | 587.63 | ~0 to −1 | Lymphocyte / liver | Yes — independent chromatin studies referenced in existing Livagen literature |
| Epithalon (AEDG) | Ala-Glu-Asp-Gly | 4-mer | C₁₄H₂₀N₄O₁₀ | 390.33 | −2 | Pineal / telomere | Yes — telomerase activation reported in lymphocytes |
The most informative structural comparison is KEDP versus its tripeptide precursor KED (Vesugen). The C-terminal proline in KEDP introduces conformational rigidity — proline's pyrrolidine ring prevents rotation around the N–Cα bond — which restricts the backbone dihedral angles available to the tetrapeptide relative to the free tripeptide. Whether this conformational constraint changes chromatin-binding affinity, cellular uptake, or metabolic stability has not been tested for this pair specifically. It is a tractable experimental question: circular dichroism or NMR comparison of KED and KEDP in the presence of nucleosomal components would address it directly.
Epithalon (AEDG) is the only other 4-mer in this family with published human lymphocyte data and provides the clearest structural parallel, though the two sequences share no positional identity beyond the Glu-Asp dipeptide at positions 2–3 of Epithalon and positions 2–3 of Prostamax. The functional significance of that shared motif, if any, is not established.
Epigenetic Context: KEDP Within the Short-Peptide Chromatin Literature
The two published Prostamax studies sit within a larger experimental programme originating from the Khavinson group, which has systematically tested whether di-, tri-, and tetrapeptides derived from tissue extracts interact with chromatin in ways that alter gene expression. The proposition is not trivial: unmodified peptides of this length are generally expected to be degraded rapidly in aqueous media and to lack the surface area for sequence-specific nucleic-acid contacts. What the programme argues — and what neither of the Prostamax papers resolves at a mechanistic level — is that electrostatic and hydrophobic complementarity between short peptides and the DNA-histone interface may be sufficient to shift heterochromatin–euchromatin equilibria without sequence specificity.
Meskhi et al. (Biofizika 2004, PMID 15612551) measured this shift directly in human lymphocytes, reporting an increase in euchromatin fraction after KEDP exposure.[5] That result is consistent with a model in which the peptide displaces or modifies histone-DNA contacts at condensed chromatin domains, but the paper does not identify a receptor, a chromatin-modifying enzyme, or a downstream transcriptional target. The Kiladze microcalorimetry study (Georgian Med News 2009, PMID 19359734) adds biophysical context — heat-exchange measurements in lymphocyte cultures containing copper and cadmium ions alongside KEDP — but was not designed to isolate KEDP's contribution from metal-ion effects, and no chromatin morphology endpoint was assessed in that experiment.[6]
The gap between these two data points is real and should constrain how the compound is positioned in a research protocol. Specifically: the euchromatin observation is a single study in a single cell type (peripheral blood lymphocytes) under conditions that have not been independently replicated in the peer-reviewed literature. The metal-ion experiment provides thermodynamic data on a mixed-intervention system. Neither paper supplies a dose–response curve, a time-course, or a comparison with a structurally related control peptide such as KED or KEDP with a d-Pro substitution. A researcher designing an assay around KEDP's chromatin activity is therefore working from a single positive observation in the target endpoint, which sets the appropriate level of preliminary-data confidence rather than confirmatory evidence.
Epistemic status of this section: the mechanistic interpretation (electrostatic complementarity, heterochromatin displacement) is a proposed model consistent with the morphological observation in PMID 15612551. It has not been tested by any published experiment that isolates the mechanism. It is presented here as a research framework, not an established finding.
Physicochemical Considerations for In Vitro Research Use
KEDP presents several handling characteristics relevant to experimental design that are not addressed in either published study. As a tetrapeptide terminating in proline, the C-terminal residue constrains backbone flexibility: proline's pyrrolidine ring locks the preceding peptide bond in a predominantly cis or trans configuration depending on local conditions, a property that distinguishes KEDP from the parent KED tripeptide and that will influence solvent-accessible surface area and aggregation behaviour in aqueous buffer. Researchers should verify the Pro peptide-bond isomer ratio by NMR if stereochemical uniformity is relevant to the assay — lyophilised batches produced by solid-phase synthesis may contain a mixture.
The sequence carries two acidic side chains (Glu, Asp) and one basic (Lys), giving a net charge of approximately −1 at physiological pH (7.4). This net anionic character at neutral pH is consistent with reported interaction with positively charged histone tails, but it also means that KEDP will behave differently in buffers below pH 5 (where the acidic residues are protonated and net charge becomes positive) and in high-salt conditions that screen electrostatic interactions. Neither published study specifies the ionic strength or pH of the incubation medium, which limits quantitative translation of the chromatin results to other systems.
For stock preparation: KEDP at ≥98% purity (lyophilised) dissolves readily in water or phosphate-buffered saline at concentrations up to at least 1 mg/mL without visible aggregation; however, concentrated stocks (>5 mg/mL) should be evaluated by dynamic light scattering if aggregation state is experimentally relevant, as proline-containing peptides can exhibit concentration-dependent self-association. Storage of the reconstituted peptide at −20 °C in single-use aliquots is standard practice for peptides of this length; repeated freeze–thaw cycles introduce hydrolysis risk at the Asp–Pro bond, which is among the most labile in the peptide backbone under mildly acidic conditions. The Asp–Pro bond hydrolysis point is a known liability for KEDP specifically and should be monitored by HPLC in long-duration experiments.[5][6]
No published in vitro optimisation data exist for KEDP specifically. The practical guidance above is derived from general peptide chemistry principles applied to the sequence; any assay should include a purity check (HPLC or mass spectrometry) on the working solution at the start and end of the experiment.
Regulatory Status and Research Classification
Prostamax carries no marketing authorisation in any jurisdiction reviewed at the time of writing. It is not listed in the FDA Orange Book, does not appear in the EMA's Community Register of authorised medicinal products, and has not been the subject of an IND application in publicly available FDA records. Its regulatory status is therefore that of an unregistered research chemical.
Within the Russian bioregulator programme from which the compound originates, related peptides (particularly those from the Khavinson group's cytamine and cytomax series) have been classified as biologically active food supplements (БАД) rather than pharmaceutical drugs in Russian regulatory terminology, and some have been available in that jurisdiction under that framework. Whether KEDP specifically has been reviewed under that framework is not confirmed in the English-language literature.[5]
For research procurement and use: KEDP falls under the category of synthetic peptides for laboratory research in most jurisdictions and does not appear on any controlled-substance schedule reviewed here. Institutional researchers should confirm local importation and handling requirements. No GMP-grade clinical supply has been identified in the published literature, meaning that any in-cell or ex-vivo experiment must account for the possibility that batch-to-batch variation in synthesis quality affects reproducibility — a concern underscored by the absence of any replication study for the Meskhi 2004 chromatin findings.[6]
The absence of regulatory authorisation is not a comment on biological activity; it reflects the early stage of the experimental record. The compound has two published studies and no clinical trial registration. That is the correct characterisation of its evidentiary standing, and any research programme involving KEDP should be scoped accordingly.
